Radar · Oncology in New York
Best Oncology Companies in New York, United States
The 177 best Oncology companies in New York, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Everest Medicines.
By Riya SenguptaFinancials
177companies tracked
$5.2Bdisclosed funding
0unicorns
119have raised
FLIAR INTELLIGENCE · ONCOLOGY × NEW YORK
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
86%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
173kcombined LinkedIn audience
38%of audience held by top 3
1companies hiring publicly (12 mo)
Ranked: Best Oncology companies in New York
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | Everest Medicines Developer of drugs for the treatment of cancer | $593M | 72 mo ago | 395 | Kerry Blanchard CEO | — | 3 partnerships |
| 2 | Goodhealth Bioscience Developer of antibody-based therapeutics to treat cancer | $385M | 60 mo ago | — | — | — | — |
| 3 | Delcath Speciality Pharmaceutical and medical device company focused on oncology 74Product top 14%Funding top 20%Fin. health top 31%Innovation top 34% All 10 signals ▾Producttop 14% Fundingtop 20% Fin. healthtop 31% Innovationtop 34% Techtop 37% Growthtop 39% Markettop 43% Moattop 47% Newstop 48% Globalbottom 44% Product: 5 distinct product lines · Company stage: Public Funding: Raised $307M across 19 rounds · 19 rounds over 24 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 74/100 | $307M | 17 mo ago | 52 | — | — | — |
| 4 | Nuvation Bio Developer of therapeutics for cancer treatment | $275M | 80 mo ago | 65 | — | 258 patents Design and synthesis of heterocyclic small‑molecule cancer drugs targeting nuclear hormone receptors. | — |
| 5 | SpringWorks Therapeutics Developer of small molecule therapeutics for treating cancer and rare diseases | $230M | 45 mo ago | 305 305 → 368 (+21%) · sector median -20% | Saqib Islam CEO | 419 patents Small‑molecule YAP/TAZ‑TEAD inhibitors and related heterocyclic oncology therapeutics | — |
| 6 | IRX Therapeutics Developing innovative cell therapies for advanced cancer and autoimmune diseases | $190M | 105 mo ago | 29 | — | — | — |
| 7 | Selecta Biosciences Developer of nanoparticle immunomodulatory drugs for treating multiple diseases | $155M | 70 mo ago | 67 | — | 957 patents Tolerogenic nanocarrier delivery systems for immune‑tolerant protein therapeutics | — |
| 8 | Zentalis Developer of small molecule therapeutics for cancer treatment | $147M | 72 mo ago | 168 168 → 123 (-27%) · sector median -20% | Kimberly Blackwell CEO | — | — |
| 9 | Athenex Developer of therapies for the treatment of multiple cancers | $147M | 78 mo ago | 318 | — | 120 patents Design of biaryl small‑molecule kinase inhibitors and oral chemo‑immunotherapy formulations | — |
| 10 | BioTheryX Developer small molecule-based therapies for cancers | $133M | 61 mo ago | 40 40 → 27 (-32%) · sector median -20% | David Stirling Founder and CEO | 261 patents Targeted protein degradation and small‑molecule therapeutics for disease treatment | — |
| 11 | Hibercell Developer of therapeutics for the treatment of solid and liquid cancers | $128M | 61 mo ago | 53 | — | 122 patents Cancer immunotherapy: GCN2 modulators, beta‑glucan/CD40 agonists, and novel crystalline drugs | — |
| 12 | Neogene Therapeutics Developer of T-cell therapy for treating cancer | $125M | 69 mo ago | 120 | Carsten Linnemann Co-Founder & CEO | — | — |
| 13 | Syros Pharmaceuticals Developer of small molecule therapeutics for cancer and genetic diseases | $124M | 45 mo ago | 117 | Conley Chee CEO | 304 patents Patents concentrated in chemistry & materials | — |
| 14 | Cleveland BioLabs Online gaming center offering slot games and deposit options | $124M | 72 mo ago | 46 | — | 139 patents TLR‑agonist immunotherapies, flagellin‑based vaccines, and radioprotective pharmaceutical agents. | — |
| 15 | C2i Genomics Provider of liquid biopsy for post cancer surgery monitoring | $112M | 62 mo ago | 64 | Ezra Sofer Co-Founder | — | — |
| 16 | Flame Biosciences Manufacturer of drugs for treating inflammation | $109M | 68 mo ago | — | Charles Fisher Founder | — | — |
| 17 | Mustang Bio Developer of CAR-T cell therapy for brain cancer and acute myeloid leukemia treatment | $95M | 31 mo ago | 80 80 → 43 (-46%) · sector median -20% | Manuel Litchman CEO | — | — |
| 18 | Accutar Biotechnology Provider of artificial intelligence-based solutions for accelerating drug discovery and development processes | $91M | 62 mo ago | 37 | Jie Fan Founder & CEO | 145 patents Design of small‑molecule kinase degraders and computational docking for oncology drugs | — |
| 19 | Treadwell Developer of therapeutics for cancer | $91M | 55 mo ago | 47 | Mark Bray Founder | — | — |
| 20 | Volastra Developer of therapeutics for cancer treatment 40Funding top 24%Talent top 28%Moat top 39%Tech bottom 48% All 6 signals ▾Fundingtop 24% Talenttop 28% Moattop 39% Techbottom 48% Globalbottom 37% Marketbottom 31% Funding: Raised $87.2M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 40/100 | $87M | 9 mo ago | 21 21 → 41 (+95%) · sector median -20% | Samuel Bakhoum Co-Founder | — | 1 job opening |
| 21 | Promontory Therapeutics Developer of immunotherapeutics for the treatment of cancer | $72M | 54 mo ago | 17 17 → 11 (-35%) · sector median -20% | Matthew Price Co-Founder & COO | — | — |
| 22 | Sapience Therapeutics Pioneering peptide therapeutics for traditionally undruggable cancer targets | $72M | 48 mo ago | 12 12 → 24 (+100%) · sector median -20% | — | — | — |
| 23 | Codagenix Developer of live-attenuated viral vaccines using proprietary SAVE technology 62Patents top 19%Moat top 21%Innovation top 24%Talent top 28% All 9 signals ▾Patentstop 19% Moattop 21% Innovationtop 24% Talenttop 28% Fundingtop 30% Marketbottom 49% Globalbottom 42% Techbottom 38% Newsbottom 27% Patents: 127 patents matched (strict assignee match) · 91 filings since 2022 vs 36 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 127 patents rank vs industry peers · Fliar Intelligence Index 62/100 | $47M | 14 mo ago | 41 | — | 127 patents Live-attenuated viral vaccine design using codon deoptimization and recombinant virus platforms | — |
| 24 | Indaptus Developer of immunotherapies for oncology and infectious diseases 19Funding top 35%Moat top 39%Talent bottom 49%Growth bottom 42% All 7 signals ▾Fundingtop 35% Moattop 39% Talentbottom 49% Growthbottom 42% Globalbottom 30% Marketbottom 24% Newsbottom 23% Funding: Raised $37.9M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Moat: Editorial + unicorn rating 6/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 19/100 | $38M | 12 mo ago | 6 | Jeffrey Meckler Chief Executive Officer | — | — |
| 25 | IN8Bio Provider of immune based therapies for the treatment of cancer 50Funding top 27%Patents top 32%Moat top 38%Innovation top 39% All 10 signals ▾Fundingtop 27% Patentstop 32% Moattop 38% Innovationtop 39% Techtop 41% Newstop 42% Growthtop 45% Talentbottom 41% Marketbottom 39% Globalbottom 36% Funding: Raised $35.0M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) Patents: 33 patents matched (strict assignee match) · 25 filings since 2022 vs 8 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $35M | 5 mo ago | 31 31 → 25 (-19%) · sector median -20% | William Ho Founder & CEO | 33 patents Engineered gamma‑delta T‑cell CAR immunotherapies for cancer treatment | — |
| 26 | Kanvas Biosciences Provider of imaging solutions for microbial research and infectious diseases 27Funding top 27%Talent top 38%Global bottom 38%Moat bottom 38% All 5 signals ▾Fundingtop 27% Talenttop 38% Globalbottom 38% Moatbottom 38% Marketbottom 27% Funding: Raised $29.5M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 27/100 | $30M | 1 mo ago | 10 | Iwijn De Vlaminck Co-Founder | — | 1 expansion |
| 27 | RenBio Developer of antibody-based therapeutic solutions for the treatment of cancer & inflammatory diseases | $29M | 21 mo ago | 10 10 → 8 (-20%) · sector median -20% | David Ho Co-Founder | 11 patents Gene therapy delivery devices and plasmid expression vectors for therapeutic proteins/peptides | — |
| 28 | ZetaGen Developer of targeted therapies for metastatic and primary breast cancers 27Talent top 15%Funding top 33%Moat top 48%Tech bottom 34% All 6 signals ▾Talenttop 15% Fundingtop 33% Moattop 48% Techbottom 34% Globalbottom 32% Marketbottom 25% Talent: Analyst team rating 5/5 Funding: Raised $20.3M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) rank vs industry peers · Fliar Intelligence Index 27/100 | $20M | 7 mo ago | 9 | — | — | — |
| 29 | AcuamarkDx Provider of non-invasive screening test for early detection of cancer | $20M | 24 mo ago | 6 | Bernard Peperstraete Cofounder & CEO | — | — |
| 30 | Lucid Diagnostics Developer of diagnostic kit for oesophagal cancer | $19M | 32 mo ago | 74 74 → 115 (+55%) · sector median -20% | Lishan Aklog Md Chairman & CEO | — | — |
| 31 | OverT Bio Developer of cell therapies to treat solid tumors | $16M | 18 mo ago | — | Neville Sanjana Co-Founder | — | — |
| 32 | Vaccinex Deveeloper of therapeutics to treat cancer and neurologic diseases | $15M | 26 mo ago | 41 41 → 28 (-32%) · sector median -20% | — | 576 patents Semaphorin‑4D inhibition and CCR8 antibody therapeutics for neurodegeneration, cognition, and atherosclerosis | — |
| 33 | Waypoint Digital cell therapy platform for providers | $14M | 23 mo ago | 9 | David Phizicky Co-founder and CSO | — | — |
| 34 | Tracer Bio Developer of ultrasensitive ctDNA assay for molecular response surveillance | $10M | 17 mo ago | — | Gopal Ramachandran Co-Founder & CSO | — | — |
| 35 | Glycotest Provider of non-invasive blood tests for liver cancers and fibrosis-cirrhosis | $7M | 28 mo ago | 2 | — | — | — |
| 36 | Starton Developer of drug delivery solution and drugs for treating oncology | $6M | 20 mo ago | 14 | Pedro Lichtinger Chairman & CEO | — | — |
| 37 | Scienture Developer of therapeutics for CNS, oncology, and cardiovascular disease | $6M | 11 mo ago | 6 | — | 24 patents Sustained‑release liquid and injectable drug formulations for cardiovascular and analgesic therapies | 3 launchs |
| 38 | Aethon Therapeutics Developer of immunotherapies for cancer treatment | $6M | 21 mo ago | 7 | Benjamin Neel Co-Founder | — | — |
| 39 | Ancilia Developer of microbiome therapies for immunology and oncology indications 19Funding top 37%Patents top 41%Innovation bottom 49%Moat bottom 49% All 7 signals ▾Fundingtop 37% Patentstop 41% Innovationbottom 49% Moatbottom 49% Globalbottom 43% Marketbottom 20% Newsbottom 18% Funding: Raised $4.2M across 6 rounds · 6 rounds over 2 yrs (3.0/yr) Patents: 11 patents matched (strict assignee match) · 9 filings since 2022 vs 2 in 2017-21 rank vs industry peers · Fliar Intelligence Index 19/100 | $4M | 4 mo ago | 5 | — | 11 patents Blockchain security analytics and microbiome modulation therapeutics | — |
| 40 | Summit Biomedical Imaging Developer of diagnostic solutions for the early detection of cancer diseases | $4M | 15 mo ago | 3 | Thomas Reiner Co-Founder & Scientific Advisor | — | — |
| 41 | POP BIO Developer of nanomedicines to treat oncology and infectious diseases | $2M | 13 mo ago | 5 | Jonathan Smyth Co-Founder | — | — |
| 42 | TEZCAT Laboratories Developing therapies for cancer treatment | $2M | 13 mo ago | — | Andrew Hauser Co-Founder & COO | — | — |
| 43 | MimiVax Disrupting cancer with innovative immunotherapies aimed at increasing patient survival rates | $2M | 11 mo ago | 3 | — | 2 patents Therapeutic anti‑survivin antibodies for cancer treatment | — |
| 44 | NanoPharmaceuticals Developer of therapeutics for cancer treatment | $1M | 16 mo ago | 2 | James Lynch CEO | 71 patents Targeted polymer‑drug conjugates for neuroendocrine and brain tumor therapy | — |
| 45 | Synthis Therapeutics Developer of therapeutics to treat cancer | $1M | 21 mo ago | 3 | Dori Karyat Founder & CEO | — | — |
| 46 | DepYmed Developer of therapeutics for rare disease and cancer | $1M | 14 mo ago | 2 | Nicholas Tonks Co-Founder | 26 patents Therapeutic copper-chelating agents and aminosteroid PTP1B inhibitors for metabolic disease treatment | — |
| 47 | HemoGenyx Developer of cell and gene therapies to treat blood diseases and viral infections | $1M | 4 mo ago | 14 | — | 6 patents Bispecific antibody-mediated depletion of hematopoietic stem/progenitor cells for conditioning transplants | — |
| 48 | PAVmed Developer of medical devices and biomarkers to detect various diseases | $845K | 4 mo ago | 107 | — | 50 patents Minimally invasive catheter systems for fluid control and fibrous tissue division. | — |
| 49 | Lixte Developer of drugs to treat cancer | $710K | 11 mo ago | 3 | — | — | — |
| 50 | MiNK Therapeutics Developer of T cell therapies for cancer and other immune-mediated diseases | $306K | 13 mo ago | 37 37 → 31 (-16%) · sector median -20% | Jennifer Buell CEO | — | — |
Top 12 Oncology companies in New York
#1
Series A · Ithaca, New York · founded 2021 · 10 employees$29.5Mraised▾
Series A · Ithaca, New York · founded 2021 · 10 employees
Provider of imaging solutions for microbial research and infectious diseases
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 27%Talent
top 38%Global
bottom 38%Moat
bottom 38%Market
bottom 27%Funding: Raised $29.5M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series A (May 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Global: Investors from 4 countries beyond United States
Audience (LinkedIn): 4k LinkedIn followers — 2.6% of this cohort's audience
Activity (LinkedIn): 1 expansions announced in 12 mo
Funding rounds
- May 2026Series A$48M
- Mar 2024Series A$12.5M
- Jun 2023Seed$11.8M
Founders & team
Investors
DCVC, Lion Capital, FemHealthVentures, Germin8, Ki Tua Fund, Pangaea Ventures
#2
Public · New York City, New York · founded 2020 · 31 employees$35Mraised▾
Public · New York City, New York · founded 2020 · 31 employees
Provider of immune based therapies for the treatment of cancer. The company offers its proprietary technology and develop genetically modified gamma-delta (γδ) T cells for targeting cold, low mutation cancers cell. It offers pipeline of drug candidates which include INB-200 for glioblastoma, INB-100 for leukemia, INB-400 for solid tumors, and others.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 27%Patents
top 32%Moat
top 38%Innovation
top 39%Tech
top 41%News
top 42%Funding: Raised $35.0M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) · Last round Post IPO (Dec 2025)
Patents: 33 patents matched (strict assignee match) · 25 filings since 2022 vs 8 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 5/10 · IP moat: 33 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 5k LinkedIn followers — 2.9% of this cohort's audience
Funding rounds
- Dec 2025Post IPO$20.1M
- Oct 2024Post IPO$12.4M
- Dec 2023Post IPO$14.4M
- Sep 2020Series C$35M
Founders & team
Investors
Bios Partners, Innovation Depot
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#3
Series B · New York City, New York · founded 2019 · 21 employees$87.2Mraised▾
Series B · New York City, New York · founded 2019 · 21 employees
Developer of therapeutics for cancer treatment. The company is developing compounds to target chromosomal instability and related pathways to inhibit genomic instability and disease progression. It also developing proprietary imaging technologies to identify chromosomal instability cancers.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 24%Talent
top 28%Moat
top 39%Tech
bottom 48%Global
bottom 37%Market
bottom 31%Funding: Raised $87.2M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) · Last round Series B (Sep 2025)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 7k LinkedIn followers — 3.9% of this cohort's audience
Hiring (LinkedIn): 5 hiring posts in 12 mo (public) · momentum -1 · hiring: Clinical Project Manager / Senior Clinical Project Manager, Senior Clinical Data Manager
Funding rounds
- Sep 2025Series B$30.1M
- May 2024Series A$15M
- Mar 2023Series A$60.2M
- Apr 2021Seed—
Founders & team
Investors
Polaris Partners, Droia, Arch Venture Partners, Vida Ventures, Catalio Capital Management, Droia Ventures
Tech stack
Anime.JsAosApple Icloud MailCloudflareCloudflare Bot ManagementCore-Js
#4
Public · New York City, New York · founded 1987 · 52 employees$306.6Mraised▾
Public · New York City, New York · founded 1987 · 52 employees
Speciality Pharmaceutical and medical device company focused on oncology. Proprietary product-Melphalan Hydrochloride Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)-is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. In the USA, the product is not yet approved for sale. In Europe, melphalan hydrochloride is marketed as a device under the name CHEMOSTAT delivery system for melphalan. The pipeline includes a number of clinical trials of high dose chemotherapy for liver cancers such as hepatocellular carcinoma, neuroendocrine tumor, and colorectal cancer
Fliar Intelligence Index™ 74how this company ranks against its industry peers
Product
top 14%Funding
top 20%Fin. health
top 31%Innovation
top 34%Tech
top 37%Growth
top 39%Product: 5 distinct product lines · Company stage: Public
Funding: Raised $307M across 19 rounds · 19 rounds over 24 yrs (0.8/yr) · Last round Post IPO (Dec 2024)
Fin. health: Revenue ~$85.2M (FY2024) · Net margin -4.3% · Revenue +129% YoY
Audience (LinkedIn): 9k LinkedIn followers — 4.9% of this cohort's audience
Funding rounds
- Dec 2024Post IPO$16.3M
- Mar 2024Post IPO$7M
- Mar 2023Post IPO$35M
- Dec 2022Post IPO$6.2M
Investors
Vivo Capital, Logos, BVF Partners, Rosalind Advisors, Stonepine, Serrado Capital
Tech stack
AccessibeAcquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform Launch
#5
Series B · Syracuse, New York · founded 2017 · 9 employees$20.3Mraised▾
Series B · Syracuse, New York · founded 2017 · 9 employees
Developer of targeted therapies for metastatic and primary breast cancers. It is a clinical-stage biopharma focused on developing first-of-its-kind therapeutics for the treatment of metastatic and primary breast cancers. It focuses on creating therapies designed to suspend cancer, inhibit pain, and regenerate bone. Its therapies are intended as adjunctive treatments, administered locally to bone or soft tissue. Its research investigates a molecular pathway with the potential to establish a new treatment paradigm for metastatic bone lesions and osteological conditions.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Talent
top 15%Funding
top 33%Moat
top 48%Tech
bottom 34%Global
bottom 32%Market
bottom 25%Talent: Analyst team rating 5/5
Funding: Raised $20.3M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) · Last round Series B (Oct 2025)
Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 530 LinkedIn followers
Funding rounds
- Oct 2025Series B$12.9M
- Jan 2025Series B$83.2K
- Aug 2023Series B$9.8M
- Feb 2023Series A$9.6M
Investors
National Cancer Institute, New York State, Consolidated Investment Group
Tech stack
AosCivicthemeComplianzGodaddyGoogle AnalyticsHttp/3
#6
Series B · New York City, New York · founded 2019 · 5 employees$4.2Mraised▾
Series B · New York City, New York · founded 2019 · 5 employees
Developer of microbiome therapies for immunology and oncology indications. It offers bacterial therapeutics that target the viral components of the microbiome to treat chronic diseases. The therapies are based on CRISPR technology that enhances bacterial immunity against viruses and modulates the human microbiome.
Fliar Intelligence Index™ 19how this company ranks against its industry peers
Funding
top 37%Patents
top 41%Innovation
bottom 49%Moat
bottom 49%Global
bottom 43%Market
bottom 20%Funding: Raised $4.2M across 6 rounds · 6 rounds over 2 yrs (3.0/yr) · Last round Series B (Feb 2026)
Patents: 11 patents matched (strict assignee match) · 9 filings since 2022 vs 2 in 2017-21 · Latest publication 2024
Innovation: 11 patents (top 82% of patent-holders) · 9 filings since 2022 vs 2 in 2017-21
Audience (LinkedIn): 4k LinkedIn followers — 2.1% of this cohort's audience
Funding rounds
- Feb 2026Series B$10.1M
- Aug 2025Grant (prize money)$274.4K
- Jul 2025Grant (prize money)$274.4K
- Sep 2024Grant (prize money)$274.4K
Investors
Safar Partners, Metaplanet, PsyMed Ventures, Zubi Capital, Spacecadet, National Science Foundation
#7
Series B · Stony Brook, New York · founded 2011 · 41 employees$47.1Mraised▾
Series B · Stony Brook, New York · founded 2011 · 41 employees
Developer of live-attenuated viral vaccines using proprietary SAVE technology. The SAVE platform relies on synthetic biology and re-design of the target virus' entire genome to yield a vaccine strain. All pipeline vaccines are currently in preclinical stages targeting seasonal influenza, dengue virus (DEV), respiratory syncytial virus (RCV), and pandemic influenza.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Patents
top 19%Moat
top 21%Innovation
top 24%Talent
top 28%Funding
top 30%Market
bottom 49%Patents: 127 patents matched (strict assignee match) · 91 filings since 2022 vs 36 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 7/10 · IP moat: 127 patents
Innovation: 127 patents (top 22% of patent-holders) · 91 filings since 2022 vs 36 in 2017-21
Funding rounds
- Apr 2025Grant (prize money)$4.4M
- Oct 2023Grant (prize money)$10M
- Feb 2023Series B$25M
- Jul 2020Grant (prize money)$4.8M
Investors
Adjuvant Capital, Topspin Fund, Euclidean Capital, Serum Institute of India, HHS, NIH
Tech stack
WordpressMysqlPhpGenesis ThemeContact Form 7Yoast Seo
#8
Public · New York City, New York · founded 2021 · 6 employees$37.9Mraised▾
Public · New York City, New York · founded 2021 · 6 employees
Developer of immunotherapies for oncology and infectious diseases. The lead candidate Decoy20 provides broad anti-tumor and anti-viral responses in combination for the treatment of colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin’s lymphoma.
Fliar Intelligence Index™ 19how this company ranks against its industry peers
Funding
top 35%Moat
top 39%Talent
bottom 49%Growth
bottom 42%Global
bottom 30%Market
bottom 24%Funding: Raised $37.9M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Post IPO (Jun 2025)
Moat: Editorial + unicorn rating 6/10 · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 1k LinkedIn followers · 24 engagements/post (1.6× cohort median)
Funding rounds
- Jun 2025Post IPO$5.7M
- Jan 2025Post IPO$2.2M
- Jul 2021Post IPO$30M
Founders & team
#9
Public · Buffalo, New York · founded 2014 · 14 employees$1Mraised▾
Public · Buffalo, New York · founded 2014 · 14 employees
Developer of cell and gene therapies to treat blood diseases and viral infections. It offers apipeline of drug candidates which include HG‑CT‑1 CAR‑T therapy for relapsed or refractory acute myeloid leukemia, CDX Bi‑specific antibody to eliminate malignancy in patients with FLT3+ R/R AML and potentially condition bone marrow transplant, and Chimeric Bait Receptor Platform for antiviral and cancer immune cell reprogramming.
Funding rounds
- Feb 2026Post IPO$3.4M
- Mar 2025Post IPO$915.1K
- Jan 2025Post IPO$425.6K
- Mar 2024Post IPO$4.5M
Investors
43North, MINT Capital, Prevail Partners, Design Technologies, VentureHealth
Tech stack
Contact Form 7CookieyesGodaddyJqueryJquery MigrateMicrosoft 365
#10
Public · New York City, New York · founded 2014 · 107 employees$845Kraised▾
Public · New York City, New York · founded 2014 · 107 employees
Developer of medical devices and biomarkers to detect various diseases. The products developed by the company include "CarpX" a minimally invasive device to treat carpal tunnel syndrome, "PortIO" a novel, implantable, intraosseous vascular access device, and "DisappEAR" antimicrobial resorbable ear tubes, and many more.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers — 2.4% of this cohort's audience
Activity: 1 awards announced in 12 mo
Funding rounds
- Feb 2026Post IPO$30M
- Feb 2025Post IPO$2.4M
- Jan 2025Post IPO$2.7M
- Sep 2024Grant (prize money)$892.1K
Investors
HHS, WI Harper Group
Tech stack
CloudflareGoogle Font ApiGoogle Hosted LibrariesGoogle Tag ManagerHstsHttp/3
#11
Public · Hauppauge, New York · founded 2019 · 6 employees$6Mraised▾
Public · Hauppauge, New York · founded 2019 · 6 employees
Developer of therapeutics for CNS, oncology, and cardiovascular disease. The company's lead candidates include SCN-101, SCN-104, and SCN-105 are used to treat CNS disease, SCN-102 is for oncology, and SCN-103 and SCN-106 are used to treat cardiovascular disease. The company is also developing therapeutics including SCN- 07 for pain, SCN-108 for endocrinology, and SCN-109 for anti-infective diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 637 LinkedIn followers
Activity: 3 product launches announced in 12 mo
Funding rounds
- Jul 2025Post IPO$1.7M
- Nov 2024Post IPO$3.3M
- Dec 2020Post IPO$6M
#12
Series A · New York City, New York · founded 2016 · 10 employees$29.2Mraised▾
Series A · New York City, New York · founded 2016 · 10 employees
Developer of antibody-based therapeutic solutions for the treatment of cancer & inflammatory diseases. The company's proprietary MYO technology involves in the development of antibody therapeutic that helps in treating rare diseases, viral infections, autoimmune diseases, and more by using DNA blueprint & antibody factory.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Funding rounds
- Aug 2024Series A$5.2M
- Jan 2021Series A$24M
- Jul 2016Grant (prize money)$3.4M
Founders & team
Investors
Ruentex Industries, Military Health
Tech stack
WordpressMysqlPhpWp RocketNginxJquery Migrate
Funding & investor landscape
$5.2Btotal disclosed funding
117companies funded
419disclosed rounds
1rounds last 90 days
Most active investors
Notable founders
Iwijn De Vlaminck
Co-Founder · Kanvas Biosciences
Matthew P Cheng
Co-Founder · Kanvas Biosciences
William Ho
Founder & CEO · IN8Bio
Samuel Bakhoum
Co-Founder · Volastra
Olivier Elemento
Co-Founder · Volastra
Jeffrey Meckler
Chief Executive Officer · Indaptus
David Ho
Co-Founder · RenBio
Yaoxing Huang
Co-Founder · RenBio
Neville Sanjana
Co-Founder · OverT Bio
Mat Legut
Co-Founder & CEO · OverT Bio
Gopal Ramachandran
Co-Founder & CSO · Tracer Bio
Mark Kaganovich
Founder & CEO · Tracer Bio
Prism market signals · United States · country-scoped Prism corpus, 1,572,524 docs
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Oncology & Cancer Therapeutics is moving in the United States
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 12,968 United States-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 52% → 67% across 2008–2026.
top research entities
- Harvard University573
- The University of Texas MD Anderson Cancer Center559
- Dana-Farber Cancer Institute413
- Johns Hopkins University356
- Cornell University352
leading researchers
Yang Liu · Yu Zhang · Hinda Najem · Wenxue Ma · Yan-Ruide Li · Murad Novruzov · Waseem Ullah Khan · Ullah Khan Inam
▲
Breakthroughs4,499 · 35%
▲ 32%→35% share
▲1.1× share momentum0 median citations90% since 2021mostly methods-led
Tumor microenvironment research is surging — US breakthrough papers rose from 124 to 1,921 since tracking began.
rising sub-themes (early→recent)
- Tumor microenvironment124→1921
- Immune system80→1464
- Immunotherapy66→1342
- Cancer research197→1345
- Cancer immunotherapy35→714
Newly emergingFlow cytometry 0→48 · Gene 0→45 · Hepatocellular carcinoma 0→42
Landmark Cancer immunotherapy using checkpoint blockade · 6,497 cites
◆
Advancements5,898 · 45%
▲ 44%→46% share
▲1.0× share momentum1 median citations89% since 2021mostly empirical
Cancer immunotherapy advancements are intensifying — advancement papers grew from 73 to 718, outpacing all new entrants.
rising sub-themes (early→recent)
- Tumor microenvironment212→2712
- Immune system142→2161
- Immunotherapy146→1778
- Cancer research238→1815
- Cancer immunotherapy73→718
Newly emergingBiomarker 0→106 · Epigenetics 0→82 · Gene 0→54
Landmark The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression · 4,937 cites
▼
Concerns1,469 · 11%
▼ 13%→11% share
▼0.8× share momentum3 median citations85% since 2021mostly reviews
Immunotherapy safety concerns are escalating — concern-flagged papers jumped from 42 to 624, now the segment's top rising topic.
rising sub-themes (early→recent)
- Immunotherapy42→624
- Tumor microenvironment65→585
- Immune system31→529
- Cancer immunotherapy27→298
- Cancer research49→277
Newly emergingOvarian cancer 0→30 · Immunogenicity 0→27 · Transcriptome 0→26
Landmark A framework for advancing our understanding of cancer-associated fibroblasts · 3,630 cites
RESEARCH HOTSPOTS · United States
Where oncology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston1020 · +0.56
New York829 · +0.56
SF Bay Area480 · +0.57
Chicago409 · +0.54
Philadelphia355 · +0.57
Los Angeles275 · +0.59
San Diego274 · +0.59
Pittsburgh235 · +0.55
Ann Arbor223 · +0.63
Atlanta204 · +0.54
PATENT SIGNAL · United States
Who's filing oncology patents in the United States
United States oncology patent filing is accelerating — 2,574 filings from 797 assignees (2016–2025), led by Bristol Myers Squibb, IO Therapeutics, UNIV California; annual filings 108→277.
2,574 filings797 assigneespeak 362/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Bristol Myers Squibb105
- IO Therapeutics91
- UNIV California88
- DANA Farber Cancer INST87
- Memorial Sloan Kettering Cancer 74
- Baylor College Medicine63
- UNIV Texas61
- Massachusetts INST Technology47
Common questions
How many Oncology companies are there in New York, United States?
Radar tracks 177 indexable Oncology companies headquartered in New York, United States that meet our profile-completeness bar.
What is the total funding raised by Oncology companies in New York, United States?
The Oncology companies in New York, United States on this list have raised a combined $5.2B in disclosed equity funding across 117 funded companies.
Which is the highest-funded Oncology company in New York, United States?
Everest Medicines is the highest-funded Oncology company in New York, United States, with $593M in disclosed equity funding.
How many Oncology companies in New York, United States are funded?
117 of the 177 Oncology companies in New York, United States on this list have disclosed at least one equity funding round.
How many Oncology unicorns are there in New York, United States?
None of the Oncology companies in New York, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in New York, United States Oncology companies?
The most active investors in New York, United States Oncology companies on this list include HHS, Design Technologies, Long Island High Technology Incubator, Alexandria, NIH.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.